Ionis Pharmaceuticals, Inc. - Common Stock (IONS)

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.

Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million.

One analyst says the six-month study was too short and the benefits could appear over time.

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.